Alvotech (OISE:ALVO) Stock Based Compensation: kr1,055 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OISE:ALVO Alvotech OISE:ALVO
55 GF Score
Price kr409.00
GF Value kr2,307.75
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Alvotech Stock Based Compensation?

Alvotech OISE:ALVO -1.21% 55 Stock Based Compensation is kr1,055 Mil as of Mar. 2026. GuruFocus rates OISE:ALVO with a GF Score™ of 55/100 and a GF Value™ of kr2,307.75 (Possible Value Trap). The stock has 7 warning signs investors should review.

Alvotech's Stock Based Compensation for the three months ended in Mar. 2026 was kr294 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was kr1,055 Mil.

Alvotech Stock Based Compensation Related Terms

Alvotech Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Alvotech's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alvotech Stock Based Compensation Chart

Alvotech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 0.00 1,293.74 2,261.32 956.29 925.19

Alvotech Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 164.02 264.59 344.60 151.98 293.94
OISE:ALVO
55GF Score
Alvotech OISE:ALVO
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alvotech Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1,055 Mil.

What does a Stock Based Compensation of kr1,055 Mil mean?
Alvotech (OISE:ALVO) has a Stock Based Compensation of kr1,055 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Alvotech and its competitors.
Is Alvotech's Stock Based Compensation too high?
Alvotech's current Stock Based Compensation is kr1,055 Mil. Overall, Alvotech has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Alvotech's Stock Based Compensation compare to PAHC and COLL?
Alvotech's Stock Based Compensation of kr1,055 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Alvotech and its competitors. Alvotech's current Stock Based Compensation is kr1,055 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alvotech stock overvalued right now?
Based on GuruFocus' analysis, Alvotech (OISE:ALVO) is currently considered Possible Value Trap. The stock's GF Value™ is kr2,307.75, compared to a current price of kr409.00 — trading 82.3% below its estimated fair value. The current Stock Based Compensation is kr1,055 Mil. Alvotech's overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Alvotech (OISE:ALVO), the current Stock Based Compensation is kr1,055 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alvotech (OISE:ALVO) Overvalued in 2026?

Based on GuruFocus' analysis, Alvotech stock appears to be undervalued. The current stock price of kr409.00 is trading 82.3% below its estimated GF Value™ of kr2,307.75. GuruFocus considers Alvotech to be Possible Value Trap.

Key valuation signals for OISE:ALVO:

  • Stock Based Compensation: kr1,055 Mil
  • GF Value™: kr2,307.75 vs. price of kr409.00 (82.3% below fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the OISE:ALVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alvotech Business Description

Other Exchanges ALVO:USAZ45:Germany
Address 9, rue de Bitbourg, Luxembourg, LUX, L-1273
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
55GF Score

Get the complete analysis for OISE:ALVO

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr409.00
Price
kr2,307.75
GF Value